top of page
Search

Patient Perspectives on Multiple Myeloma: Disease Perception, Quality of Life and Mental Health in China

Writer: Wendong Chen
Wendong Chen
2 hours ago
2 min read

Recently, a collaborative research study involving Normin Health and clinical teams from the Second and Third Hospitals of Hebei Medical University, titled "Disease perception, quality of life and mental health among Chinese patients with transplant-eligible newly diagnosed multiple myeloma following treatment: a cross-sectional survey study," was successfully published in the Journal of Comparative Effectiveness Research. As treatment outcomes alone may not fully capture the burden experienced by patients with multiple myeloma (MM), this study examined disease awareness, health-related quality of life (HRQoL), and psychological well-being following treatment, providing patient-centered evidence to inform supportive care and treatment decision-making.


Key Highlights of the Study:

Patient-Centered Survey Design: This cross-sectional survey was conducted between January and June 2025 at two tertiary hospitals in Hebei, China. The final analysis included 53 transplant-eligible patients with newly diagnosed multiple myeloma (NDMM) who had completed induction therapy and achieved at least a partial response. Patient questionnaires were combined with electronic medical record data. Disease perception, HRQoL, anxiety, and depression were assessed using study-specific questions and standardized instruments, including EQ-5D-5L, EQ-VAS, GAD-7, and PHQ-9. Patients were grouped according to whether they had received autologous stem cell transplantation (ASCT) for exploratory descriptive comparisons.


Major Findings:

Knowledge Gaps in Disease Awareness: Patients more commonly recognized visible or symptomatic manifestations, including bone pain (90.6%) and fatigue (84.9%). However, only 50.9% recognized renal impairment as a potential MM-related complication, and 67.9% recognized bleeding and anemia as early symptoms. These findings indicate opportunities to strengthen patient education on less apparent organ damage and hematologic complications.

HRQoL and Anemia: The mean EQ-5D-5L utility score was 0.849 (SD, 0.233), and the mean EQ-VAS score was 71.8 (SD, 19.7). Anemia was significantly associated with lower EQ-5D utility (regression coefficient, -0.253; 95% CI, -0.444 to -0.062; p = 0.011), highlighting the importance of assessing anemia-related health impact alongside disease response.

Psychological Well-Being and Disease Progression: The mean GAD-7 and PHQ-9 scores were 4.7 (SD, 6.2) and 3.1 (SD, 3.4), respectively; 13.2% of patients had moderate-to-severe anxiety and 22.6% had mild-or-greater depressive symptoms. Progressive disease was significantly associated with higher anxiety scores (coefficient, 7.963; 95% CI, 3.804 to 12.122; p < 0.001) and depression scores (coefficient, 3.358; 95% CI, 1.091 to 5.624; p = 0.005), underscoring the relevance of psychological assessment, particularly for patients with disease progression.

Patient-Reported Treatment Challenges Across Pathways: Compared with ASCT recipients, non-ASCT patients more frequently reported high treatment costs (88.2% vs 68.4%) and limited medical insurance reimbursement (70.6% vs 47.4%). These subgroup comparisons were descriptive, and the differences in reported financial challenges were not statistically significant. They should not be interpreted as determinants of treatment selection or as evidence of treatment effects.

Clinical and Policy Implications:

These findings highlight the importance of integrating patient perspectives into MM care. Structured education on renal impairment and anemia, routine assessment and management of anemia-related symptoms, and psychological screening for patients with progressive disease may help address needs that are not fully captured by conventional clinical endpoints. The patient-reported financial and reimbursement challenges also point to the value of financial counseling and further research incorporating objective cost and out-of-pocket expenditure data.


Click here to view the full article for more details and conclusions. 

 
 
 

Comments


© 2024 by Normin Health Consulting Ltd

Proudly created with wix.com

bottom of page